Interim report January-March 2013: High growth and

First quarter

Continuing operations:

  · Sales growth was 27 percent in local currency. Sales amounted to SEK 105
(86) million, corresponding to an increase of 22 percent in SEK.
  · Operating income (EBIT) amounted to SEK 17 (10) million, corresponding to an
operating margin of 16 (12) percent.
  · Net income amounted to SEK 12 (7) million, which gave earnings per share of
SEK 0.61 (0.38).

After the end of the period

  · During 2010 Vitrolife entered into a collaboration agreement with the Danish
company HertArt ApS with a view to developing a new range of disposable plastic
products for IVF under the name of Labware. Vitrolife acquired 25 percent of the
shares in HertArt as part of the collaboration agreement. On April 1, 2013
Vitrolife exercised an option to acquire all the shares in the company.

Gothenburg, April 19, 2013

VITROLIFE AB (publ)

Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
19, 2013 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global medical device
Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area
develops, produces and markets products for the treatment of human infertility.
Work is also carried out to enable the use and handling of stem cells for
therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 230
employees and the company's products are sold in almost 100 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan and Hungary. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January-March 2013: High growth and increased income

Attachments
